In another multi-omics study, the integrated analysis of gene copy number alterations, mutations, and proteome expression profiles enabled the identification of two distinct subtypes of pancreatic cancer based on the response to the mTOR (mechanistic target of rapamycin kinase)-targeting drugs [87]. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.